NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.

How NICE International is supporting evidence-based decision-making through the Regulatory Partnership for Growth Fund ...

Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults. Last reviewed: ...

Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair ...

NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines Optimisation and Chemotherapy Clinical Reference Groups (CRGs ...

Evidence-based recommendations on anhydrous sodium thiosulfate (Pedmarqsi) for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours. Last ...

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.

Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over. Last reviewed: 10 July 2024 Next review: This guidance will be ...

Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over. Commercial ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...